@article {8038,
	title = {Primary mediastinal large B-cell lymphoma: Clinical study of a distinct clinical entity and treatment outcome in 20 patients: Review of the literature},
	journal = {American Journal of Clinical Oncology: Cancer Clinical Trials},
	volume = {27},
	year = {2004},
	note = {Cited By :5Export Date: 21 February 2017},
	month = {2004},
	pages = {312 - 316},
	abstract = {Primary mediastinal B-cell lymphoma (PMBCL) is a discrete subset of large B-cell lymphoma with unique clinicopathologic features. The question of optimal treatment emerges because it is an uncommon but not rare occurrence. A retrospective study was therefore conducted in a group of patients in Greece to evaluate the clinical features and treatment outcome in this disease. Twenty patients with PMBCL, with a median age of 42 years, treated at centers participating in the Hellenic Cooperative Oncology Group over the last 20 years, were reviewed. Thirteen (65\%) had bulky disease at the time of presentation, 7 (35\%) had superior vena cavae obstruction, and 15 (75\%) had extranodal involvement. All received doxorubicin-containing chemotherapy, followed in 11 cases by mediastinal radiotherapy. With a median follow-up of 91 months, the median survival is 67.7 months. These data are consistent with those reported from other centers concerning the patient{\textquoteright}s characteristics, natural history, response pattern to chemoradiation therapy, and prognosis. Response to therapy proved of prognostic significance. A key question that remains is the prompt identification of patients who would benefit from innovative or more intensive therapies.},
	keywords = {Primary mediastinal B-cell lymphoma, Review, Treatment Outcome},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-2942560176\&doi=10.1097\%2f01.COC.0000071417.95845.06\&partnerID=40\&md5=cf82ba082822000b8729b60a1805cbd1},
	author = {Andreopoulou, H. and Pectasides, D. and Dimopoulos, M.A. and Nikolaides, C. and Fountzilas, G. and Valsami, S. and Economopoulos, T.}
}
